By Cecilia Butini

Novartis AG said Monday that a study on a drug to treat adult paroxysmal nocturnal hemoglobinuria, a red blood cell condition, has met its two primary endpoints.

The trial studied a drug named Iptacopan and established its superiority to a previously used treatment in helping patients with debilitating anemia who would normally undergo blood transfusions, according to the company.

"Iptacopan was well tolerated with a favorable safety profile consistent with previously reported data," Novartis said.

Write to Cecilia Butini at cecilia.butini@wsj.com

(END) Dow Jones Newswires

October 24, 2022 01:44 ET (05:44 GMT)

Copyright (c) 2022 Dow Jones & Company, Inc.
Novartis (NYSE:NVS)
Gráfica de Acción Histórica
De Mar 2024 a Abr 2024 Haga Click aquí para más Gráficas Novartis.
Novartis (NYSE:NVS)
Gráfica de Acción Histórica
De Abr 2023 a Abr 2024 Haga Click aquí para más Gráficas Novartis.